Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
SYNDESI THERAPEUTICS from Wavre, company number BE0686599355, closed financial year 2025 with a result of € -12 million after tax. For that financial year SYNDESI THERAPEUTICS recorded a gross margin of € -6.5 million and equity of € -129.9 million. Compared with financial year 2024, the result moved from € -60.6 million to € -12 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ -129.9 million
▼ € 12 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -12 million
▲ 80 % less loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -159.2 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 157,623
▲ 30% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2021 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -5,233,353 | € -46,967,167 | € -49,488,494 | € -6,461,490 | ▲ € 43 million |
| Profit after taxes | € -6,253,861 | € -46,558,722 | € -60,564,073 | € -11,956,947 | ▲ € 48.6 million |
| Equity | € 6,204,838 | € -57,400,776 | € -117,964,848 | € -129,921,795 | ▼ € 12 million |
| Total debts | € 2,002,045 | € 58,085,516 | € 119,598,122 | € 130,529,327 | ▲ 9% |
| Cash | € 6,480,285 | - | - | - | |
| Retained profit | € -20,549,027 | € -86,697,052 | € -147,261,123 | € -159,218,070 | ▼ € 12 million |
| Bank debt | € 1,298,693 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 8,206,883 | € 684,740 | € 1,633,274 | € 607,532 | ▼ 63% |
Key figures of SYNDESI THERAPEUTICS, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SYNDESI THERAPEUTICS?
What happened at SYNDESI THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Erica Silbiger stepped down as director. NBB
- Renaud Decroix stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 12 million. Source: NBB ↗
- Erica Silbiger became a director. NBB
- Rolfe van de Spreng stepped down as director. NBB
- Rolfe van de Spreng became a director. NBB
- Jean Antoine de Los Frailes stepped down as director. NBB
- Jean Antoine de Los Frailes became a director. NBB
In short
From € 6.3 million loss in 2021 to € 12 million loss in 2025.
Management
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Avenue Einstein 14
1300 Wavre
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
ABBVIE - AbbVie, Inc., US
Domain
Domain
syndesitherapeutics.com
Registered
2017-12-10
Registrar
MarkMonitor Inc.
Expires
2026-12-10
Website info
Features
Security
Details
- Company number
- 0686.599.355
- VAT number
- BE 0686.599.355
- Registered office
- Avenue Einstein 14, 1300 Wavre
- Names & denominations
- SYNDESI THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 December 2017
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied